BMY News and Press, Bristol-Myers Squibb Company From 06/04/24

2024-06-04 10:26:59 ET More on Bristol-Myers Squibb Company Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be...

2024-06-04 09:00:00 ET Summary Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline....

2024-06-03 04:06:40 ET Summary S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth. Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales ...

2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...

2024-06-01 09:00:00 ET Summary This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks ...

2024-06-01 08:53:44 ET More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-...

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care chemotherapy Late-breaking data featured in an oral presentation at the 2024 Ameri...

2024-05-31 16:31:58 ET More on Immunocore Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M Cantor sees strong year ahead for oncology M&A Seeking Alpha’s Quant Rating on Immunocore Historical earnings data for Immuno...

2024-05-31 12:19:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports positive Phase 3 data for remibrutinib for chronic hives Novartis end...

2024-05-30 12:22:21 ET More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-...